Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical announced the resignation of joint company secretary David Wood, leaving Tim Luscombe as the sole company secretary responsible for ASX communications, underscoring continuity in the company’s governance framework amid its ongoing efforts to commercialize its pancreatic cancer treatment device.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical develops targeted intratumoural Phosphorus-32 microparticle therapies for unresectable locally advanced pancreatic cancer, positioning its CE-marked OncoSil device within interventional oncology markets across more than 30 countries, including the EU, UK, Türkiye, and Israel.
Average Trading Volume: 25,613
Technical Sentiment Signal: Sell
Current Market Cap: A$15.11M
For an in-depth examination of OSL stock, go to TipRanks’ Overview page.